Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: BioCardia is a clinical-stage biotechnology company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous mononuclear cell therapy for ischemic heart failure and chronic myocardial ischemia, and an allogeneic mesenchymal stem cell (MSC) therapy. The company also develops the Helix transendocardial biotherapeutic delivery system.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $58 |
| Net Loss | $(4,761) | $(3,913) |
| Net Loss Per Share (Basic & Diluted) | $(0.98) | $(2.20) |
| Cash and Cash Equivalents (End of Period) | $980 | $1,421 |
| Net Cash Used in Operating Activities | $(3,267) | $(2,842) |
| Net Cash Provided by Financing Activities | $1,877 | $3,163 |
| Total Assets | $2,089 | $3,724 |
| Total Liabilities | $3,975 | $2,887 |
| Stockholders' Equity (Deficit) | $(1,886) | $(1,961) |
Debt and Liquidity: The company has no senior debt listed on the balance sheet but carries operating lease liabilities of $745,000. As of June 30, 2025, the company held $980,000 in cash and cash equivalents.
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for the six months ended June 30, 2025, compared to $58,000 in the prior year period. The company currently has no significant revenue streams.
- Operating Expenses: Total costs and expenses increased to $4.78 million for the six months ended June 30, 2025, from $3.98 million in the prior year.
- R&D Expenses: Increased to $2.90 million (from $2.04 million) primarily due to closeout activities in the CardiAMP Heart Failure Trial and enrollment in the CardiAMP Heart Failure II Trial.
- SG&A Expenses: Remained relatively flat at $1.88 million (from $1.94 million), driven by lower professional fees and share-based compensation offsetting other costs.
- Net Loss: Net loss increased to $4.76 million (from $3.91 million) due to higher R&D spend and lack of revenue.
- Cash Position: Cash decreased by $1.39 million during the period, driven by operating cash outflows partially offset by financing proceeds.
Guidance, Outlook, Risks, and Unusual Items
Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With $980,000 in cash as of June 30, 2025, the company estimates it will not have sufficient funds to meet obligations beyond October 2025 without additional financing.
Financing Activities: The company raised capital through multiple private placements and At-The-Market (ATM) offerings in the first half of 2025:
- April 2025: Sold 406,818 shares and warrants for gross proceeds of $775,000.
- June 2025: Sold 274,696 shares and warrants for gross proceeds of $570,000.
- ATM Offerings: Sold 221,378 shares for gross proceeds of $562,000 during the six-month period. Subsequent to period end (July-August 2025), an additional 296,422 shares were sold for $769,000.
Regulatory and Clinical Outlook:
- CardiAMP HF Trial: Two-year results showed statistically significant composite endpoints in patients with elevated NTproBNP. Data submitted to Japan's PMDA; FDA meeting expected in Q4 2025.
- CardiAMP HF II: Phase 3 trial enrollment has commenced.
- CardiAMP CMI: Roll-in cohort results showed improved exercise tolerance and reduced angina episodes.
Risk Factors:
- Nasdaq Compliance: The company is not in compliance with Nasdaq minimum stockholders' equity requirements ($2.5 million). It received an extension until September 29, 2025, to regain compliance. Failure to comply could result in delisting.
- Funding Risk: Continued operations depend on raising additional capital, which may be dilutive or require relinquishing rights to technologies.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the October 2025 liquidity horizon.
- Nasdaq Compliance Plan: Monitor the company's progress in regaining compliance with Nasdaq listing rules by the September 29, 2025 deadline.
- Dilution Impact: Assess the impact of recent and potential future equity issuances (ATM and private placements) on existing shareholders.
- Clinical Milestones: Track the outcome of the anticipated Q4 2025 FDA meeting regarding the CardiAMP Heart Failure data.
- Revenue Recognition: Confirm if any collaboration agreements or product sales will generate revenue in the coming quarters to offset operating losses.